Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of The Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Standard Fluzone® in Ambulatory Elderly Subjects

NCT00388583 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00388583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00388583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of The Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Standard Fluzone® in Ambulatory Elderly Subjects
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2006
Completion date
September 30, 2008
Enrollment
817 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, myxovirus infection, orthomyxoviridae infection